Navigation Links
Regulus Provides Update on 'Road to the Clinic' Strategy and Reports First Quarter 2013 Financial Results and Recent Highlights
Date:5/14/2013

continue to focus our efforts on preparing for a successful transition to a clinical-stage company and remain on track to nominate our second microRNA candidate for clinical development by the end of the year.  Our recent progress is encouraging and we look forward to realizing the potential that our microRNA technology may have in transforming the field of drug discovery."

Neil W. Gibson , Ph.D., Chief Scientific Officer, added, "We believe that RG-101 is a novel, pan-genotypic agent that may play an important role in future HCV therapy. We are very encouraged by the pre-clinical data seen to date, which includes activity against some of the known mutations that lead to resistance to the current HCV therapies and a favorable potency and PK profile which supports a once-a-month dosing paradigm.  We believe that RG-101 may be useful in difficult-to-treat HCV patients in combination with existing and emerging therapies and we look forward to exploring its clinical utility."

Garry E. Menzel , Ph.D., Chief Operating Officer and Executive Vice President of Finance, said, "As we prepare for clinical activity with RG-101, Regulus continues to maintain a strong financial position with over $90 million in cash at quarter-end. We remain on track to achieve our stated goals of finishing 2013 with at least $60 million in cash, while maintaining a burn rate of approximately $30 million to $35 million."

Recent Highlight

  • Selected New Opportunity in Oncology.  Regulus also announced today that it has selected microRNA-221 (miR-221) as an attractive target for potential clinical evaluation in patients with hepatocellular carcinoma (HCC).  Regulus is currently conducting target validation activities and expects to report further progress on this opportunity in the second half of 2013.
  • First Quarter 2013 Financial Results & Highlights Regulus reported a net loss o
    '/>"/>

    SOURCE Regulus Therapeutics Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. Regulus Announces Timing for First Quarter 2013 Financial Results Webcast and Conference Call
    2. Regulus Appoints William H. Rastetter, Ph.D. to its Board of Directors
    3. Regulus to Present at Future Leaders in the Biotech Industry Conference
    4. Regulus to Present at Cowen and Company 33rd Annual Healthcare Conference
    5. Regulus Reports Fourth Quarter and Year-End 2012 Financial Results and Highlights
    6. Regulus Announces Timing for Fourth Quarter and Year-End 2012 Financial Results Webcast and Conference Call
    7. Regulus to Present at Two Upcoming Investor Conferences
    8. Regulus Appoints Mark G. Foletta to its Board of Directors
    9. Regulus Reports Third Quarter 2012 Financial Results and Recent Highlights
    10. Regulus Announces Timing for Third Quarter 2012 Financial Results Webcast and Conference Call
    11. Regulus Appoints Douglas E. Williams, Ph.D. to its Board of Directors
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/29/2014)... SILVER SPRING, Md. , Aug. 29, 2014 /PRNewswire/ ... today that the U.S. District Court for the District ... in its favor in the company,s case against Sandoz, ... opinion, Judge Peter Sheridan ruled that U.S. ... Sandoz, Inc., and enjoined Sandoz from marketing its generic ...
    (Date:8/29/2014)... DALLAS , August 29, 2014 ... Synthesis Market by Product & Services (Equipment, Reagent, ... Biotechnology), Application (Diagnostics, PCR, QPCR, Gene Synthesis, NGS, ... by MarketsandMarkets, the global Oligonucleotide Synthesis Market is ... $1,070.7 Million in 2014, growing at a CAGR ...
    (Date:8/29/2014)... Aug. 29, 2014  Unilife Corporation ("Unilife" or "Company") ... that it intends to release its financial results for ... 30, 2014 after market trading ends on Tuesday, September ... conference call for 4:30 p.m. U.S. EDT on Tuesday, ... a.m. AEST), to review the Company,s financial results, commercial partnerships, ...
    Breaking Medicine Technology:District Court Decision Received In Remodulin Patent Case 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4Unilife Corporation to Announce Financial Results for Fiscal Year 2014 Fourth Quarter and Year End on Tuesday, September 9, 2014 2
    ... September 15 NicOx S.A. (Euronext,Paris: COX) today ... study for naproxcinod in 1020 patients with osteoarthritis ... naproxcinod (750 mg and 375 mg bid) met,the ... study,also comfortably met the main secondary endpoint, demonstrating ...
    ... ... Osteoarthritis, WALTHAM, ... announced today that Kenneth Kornman, Ph.D.,the company,s Chief Scientific Officer, ... (OA) at the 2008 World Congress,on Osteoarthritis, sponsored by the ...
    Cached Medicine Technology:NicOx Announces Second Naproxcinod Pivotal Phase 3 Study (302) Meets Efficacy Primary Endpoints and Supports Non-Detrimental Blood Pressure Effect 2NicOx Announces Second Naproxcinod Pivotal Phase 3 Study (302) Meets Efficacy Primary Endpoints and Supports Non-Detrimental Blood Pressure Effect 3NicOx Announces Second Naproxcinod Pivotal Phase 3 Study (302) Meets Efficacy Primary Endpoints and Supports Non-Detrimental Blood Pressure Effect 4NicOx Announces Second Naproxcinod Pivotal Phase 3 Study (302) Meets Efficacy Primary Endpoints and Supports Non-Detrimental Blood Pressure Effect 5Interleukin Genetics to Present Important New Findings at 2008 World Congress on Osteoarthritis 2Interleukin Genetics to Present Important New Findings at 2008 World Congress on Osteoarthritis 3Interleukin Genetics to Present Important New Findings at 2008 World Congress on Osteoarthritis 4
    (Date:8/30/2014)... Colorado (PRWEB) August 30, 2014 Daily Gossip ... called the Make Him Desire You program, who shows a ... , The author of this method says that the program ... , The Make Him Desire You review indicates that the ... amazing insider advice and his great techniques to make a ...
    (Date:8/30/2014)... 2014 Daily Gossip reveals in its recently ... a method created by Sarah Summer, who can perfectly understand ... of this new program actually had to deal with this ... be able to access it, in an all-natural holistic cure ... finding an effective cure for yeast infection. The author of ...
    (Date:8/30/2014)... New York (PRWEB) August 30, 2014 ... combination of Nutrition and Pharameuticals. Nutraceuticals is a ... extracting healthy ingredients from natural food sources. Nutraceutical ... health benefits to the human body. Nutraceutical health ... diet supplements, fortified foods and more. Although nature ...
    (Date:8/30/2014)... August 30, 2014 Ticket Down ... Open Tennis Championship tickets in NYC. This ... code US-OPEN-2014 for all day session, evening session, courtside ... sales for this prestigious Grand Slam Tournament. , The ... 8/30/14 , US Open Tennis Championship: Men's/Women's 3rd Round ...
    (Date:8/30/2014)... After offering hyperbaric oxygen therapy ... past several years, Dr. Roy Schmidt and the ... a scholarship program for veterans who have been ... held this summer to discuss veterans’ needs ( ... shed light on the large number of veterans ...
    Breaking Medicine News(10 mins):Health News:Make Him Desire You Review Reveals Powerful Formula to Make a Man Emotionally Addicted 2Health News:Natural Cure for Yeast Infection Review Exposes New Natural Treatment 2Health News:A Granular Analysis of the Nutraceutical Ingredients Market by Transparency Market Research 2Health News:A Granular Analysis of the Nutraceutical Ingredients Market by Transparency Market Research 3Health News:A Granular Analysis of the Nutraceutical Ingredients Market by Transparency Market Research 4Health News:US Open Tennis Tickets: Ticket Down Slashes Ticket Prices for Labor Day Weekend Sessions and More 2Health News:US Open Tennis Tickets: Ticket Down Slashes Ticket Prices for Labor Day Weekend Sessions and More 3Health News:US Open Tennis Tickets: Ticket Down Slashes Ticket Prices for Labor Day Weekend Sessions and More 4Health News:US Open Tennis Tickets: Ticket Down Slashes Ticket Prices for Labor Day Weekend Sessions and More 5Health News:Tennessee Hyperbaric Center Offering HBOT Scholarships to Veterans 2
    ... Ophthalmology hosts event October 24 benefiting,Juvenile Diabetes Research ... Oct. 17 Oklahoma Academy of,Ophthalmology (OAO) hosts ... Research Foundation (JDRF) Central Oklahoma Chapter., Actor, ... the,event. Lorena and Gary Story of Oklahoma City ...
    ... (Caltech) have created a "plug-and-play" synthetic RNA device--a sort ... in and responding to more than one biological or ... such devices could have a multitude of potential medical ... tumor cells or determine when to turn modified genes ...
    ... Behind New Resource, KUMASI, Ghana, Oct. 17 ... new hopeXchange Medical Center, a high quality,diagnostic and ... the ceremony, President Kufuor welcomed a high-profile mission,delegation ... the Cure(R),s President,and CEO Hala Moddelmog, and acknowledged ...
    ... MINNETONKA, Minn., Oct. 17 Cancer and its ... amounts of calories,protein and nutrients they need to help ... lose significant amounts of lean,muscle mass and weight because ... strong aversion to foods. These symptoms can lead to ...
    ... Mich., Oct. 17 Chrysler LLC and Henry,Ford ... bring an,innovative diabetes program to its Sterling Stamping ... the Henry Ford Health System,and is intended to ... existing workplace wellness initiatives. All employees at the,site ...
    ... Satyam Computer,Services Ltd. (NYSE: SAY ), a ... reported US GAAP results for its second,quarter, which ... Despite a challenging market that impacted several key ... exceeded its guidance in,the second quarter. Revenue was ...
    Cached Medicine News:Health News:Second Annual 'Eye Ball' Fights Juvenile Diabetes, Says Oklahoma Academy of Ophthalmology 2Health News:Second Annual 'Eye Ball' Fights Juvenile Diabetes, Says Oklahoma Academy of Ophthalmology 3Health News:Caltech engineers build first-ever multi-input 'plug-and-play' synthetic RNA device 2Health News:New Specialty Hospital Dedicated in Ghana is Key Component of Susan G. Komen for the Cure(R)'s Debut in Africa 2Health News:New Specialty Hospital Dedicated in Ghana is Key Component of Susan G. Komen for the Cure(R)'s Debut in Africa 3Health News:New Specialty Hospital Dedicated in Ghana is Key Component of Susan G. Komen for the Cure(R)'s Debut in Africa 4Health News:Strong Bodies Battle Better 2Health News:Strong Bodies Battle Better 3Health News:Chrysler LLC Launches Workplace Diabetes Education Program 2Health News:Satyam Posts 28 Percent Year-over-Year Revenue Growth in Second Quarter Despite Slowdown in Key Markets 2Health News:Satyam Posts 28 Percent Year-over-Year Revenue Growth in Second Quarter Despite Slowdown in Key Markets 3Health News:Satyam Posts 28 Percent Year-over-Year Revenue Growth in Second Quarter Despite Slowdown in Key Markets 4Health News:Satyam Posts 28 Percent Year-over-Year Revenue Growth in Second Quarter Despite Slowdown in Key Markets 5Health News:Satyam Posts 28 Percent Year-over-Year Revenue Growth in Second Quarter Despite Slowdown in Key Markets 6Health News:Satyam Posts 28 Percent Year-over-Year Revenue Growth in Second Quarter Despite Slowdown in Key Markets 7Health News:Satyam Posts 28 Percent Year-over-Year Revenue Growth in Second Quarter Despite Slowdown in Key Markets 8Health News:Satyam Posts 28 Percent Year-over-Year Revenue Growth in Second Quarter Despite Slowdown in Key Markets 9Health News:Satyam Posts 28 Percent Year-over-Year Revenue Growth in Second Quarter Despite Slowdown in Key Markets 10
    ... to having been designed exclusively for vascular treatments, ... the Smartepil range which ensures fast amortisation of ... systems, it can be fitted with a polarised ... the target to be treated as well as ...
    ... SmartLite Derm is a KTP laser, ... of 532 nm (frequency doubled Nd:YAG) for ... by the comfortable color LCD Touch-screen. ... available are 0.3, 0.5, 0.7 and 1.0 ...
    ... a new and powerful instrument for ... system (MEL @308 nm - UVB) ... vitiligo. Designed to treat recalcitrant plaques, ... exposure of extensive lesions without irradiating ...
    ... a CO2 laser system with CW intensities ... dealing with all therapeutic application in modern ... medium-to-high intensities in super-pulsed mode, designed for ... It is also capable of supplying soft ...
    Medicine Products: